Adult Healthy Volunteers Study to Evaluate ALPN-101 Safety

• ClinicalTrials.gov Identifier: NCT03748836
• Recruitment Status: Completed
• First Posted: November 21, 2018
• Last Update Posted: December 5, 2019
• Sponsor: Alpine Immune Sciences, Inc.
• Collaborator: Clinical Network Services (CNS) Pty Ltd
• Information provided by (Responsible Party): Alpine Immune Sciences, Inc.

Study Description

Brief Summary:

This study is testing the safety, tolerability, pharmacokinetics (PK--the amount of study drug in the blood), pharmacodynamics (PD), how the study drug affects the body) and immunogenicity (how the study drug affects the immune system) of single and multiple doses and dose levels of an investigational drug called ALPN-101.

Condition or disease	Intervention/treatment	Phase
Healthy Volunteers	Drug: ALPN-101; Drug: Placebo	Phase 1

Detailed Description:

AIS-A01 is a phase 1, randomized, placebo-controlled, double-blinded study in healthy volunteers. It will be conducted at a single center and will enroll approximately 104 participants. The study will have 2 parts:

• In Part A, participants will receive a single dose of study drug or placebo. Multiple dose levels of ALPN-101 will be evaluated.
• In Part B, participants will receive 4 doses of ALPN-101 or placebo--1 dose each week for 4 weeks. Multiple dose levels of ALPN-101 will be evaluated.

In each Part, safety assessments will be performed throughout the dosing and follow-up periods, and multiple PK and PD samples will be collected.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 96 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Randomized, placebo-controlled, double-blinded, dose escalation to evaluate the safety, PK, and PD of single and multiple doses of ALPN-101
• Masking: Double (Participant, Investigator)
• Masking Description: Double blinded, placebo-controlled
• Primary Purpose: Other
• Official Title: A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-101 in Adult Healthy Volunteers
• Actual Study Start Date: January 29, 2019
• Actual Primary Completion Date: November 18, 2019
• Actual Study Completion Date: November 18, 2019

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Single Ascending Dose ALPN-101	Drug: ALPN-101; Single or multiple doses of ALPN-101 delivered via intravenous or subcutaneous injection. Ascending dose levels will be evaluated.
Placebo Comparator: Single Dose Placebo	Drug: Placebo; Single or multiple doses of placebo delivered via intravenous or subcutaneous injection, matched to ALPN-101 cohorts.
Active Comparator: Multiple Ascending Dose ALPN-101	Drug: ALPN-101; Single or multiple doses of ALPN-101 delivered via intravenous or subcutaneous injection. Ascending dose levels will be evaluated.
Placebo Comparator: Multiple Dose Placebo	Drug: Placebo; Single or multiple doses of placebo delivered via intravenous or subcutaneous injection, matched to ALPN-101 cohorts.

Outcome Measures

Primary Outcome Measures :

1. Safety, as assessed by adverse events according to CTCAE v5.0 [ Time Frame: From study Day 1 (dosing of ALPN-101 or placebo) until the End of Study visit (approx. 4-8 weeks) ]
   The rate of adverse events will be compared between the 2 treatment groups.

Secondary Outcome Measures :

1. Pharmacokinetics of ALPN-101 as assessed by time of maximum ALPN-101 concentration. [ Time Frame: From study Day 1 (dosing of ALPN-101 or placebo) until the End of Study visit (approx. 4 weeks for Part A of the study, and approx 6 weeks for Part B) ]
   Plasma levels of ALPN-101 will be serially evaluated following dosing of study drug, and the time of maximum plasma concentration (Tmax) will be identified.
2. Pharmacokinetics of ALPN-101 as assessed by the maximum concentration of ALPN-101. [ Time Frame: From study Day 1 (dosing of ALPN-101 or placebo) until the End of Study visit (approx. 4 weeks for Part A of the study, and approx 6 weeks for Part B) ]
   Plasma levels of ALPN-101 will be serially evaluated following dosing of study drug, and the maximum plasma concentration (Cmax) will be calculated.
3. Pharmacokinetics of ALPN-101 as assessed by AUC on all subjects. [ Time Frame: From study Day 1 (dosing of ALPN-101 or placebo) until the End of Study visit (approx. 4 weeks for Part A of the study, and approx 6 weeks for Part B) ]
   Plasma levels of ALPN-101 will be serially evaluated following dosing of study drug, and the area under the curve (AUC) will be calculated.
4. The incidence of ADA against ALPN-101 will be assessed and summarized. [ Time Frame: From study Day 1 (dosing of ALPN-101 or placebo) until the End of Study visit (approx. 4 weeks for Part A of the study, and approx 6 weeks for Part B) ]
   The incidence of ADA against ALPN-101 will be assessed by the percentage of patients with a positive ADA result of all the treated patients.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

1. Able to participate and willing to give written informed consent.
2. Healthy adult participant 18 to 65 years of age, inclusive, at the time of informed consent.
3. BMI between 18 and 30 kg/m2, inclusive.
4. Male participants must agree to use a highly effective method of contraception consistently and correctly during the treatment period and for at least 30 days after the last dose of study intervention and to refrain from donating sperm during this period.

5. Female participants must not be pregnant or breastfeeding

   Exclusion Criteria:

   General Health Exclusions

6. Any concomitant disease, condition or treatment that could interfere with the conduct of the study or that would, in the opinion of the Investigator or Sponsor, pose an unacceptable risk to the participant in the study or interfere with the interpretation of study data.
7. History or symptoms of significant psychiatric disease in the opinion of the Principal Investigator, including but not limited to depression and schizophrenia.
8. History of immunological disorders, auto-immune disorders, acquired or congenital immune deficiency.
9. History of significant hepatic or renal disease or impairment.
10. Evidence of an active or suspected cancer or a history of malignancy within the previous 3 years, except for the following, which did not require systemic therapy and are considered cured: nonmelanoma skin cancer, curatively treated localised prostate cancer or other in situ cancer.
11. History of major organ transplantation with an existing functional graft. Therapeutic and Intervention-Related Exclusions
12. Use of prescription medications or herbal remedies within 14 days or 5 elimination half-lives (whichever is longer) of study intervention administration or use of over-the-counter medications (OTC) within 7 days of study intervention administration (apart from recommended doses of vitamin/mineral supplements, OTC analgesics, etc., approved by the Investigator and Sponsor). Participants who have been on hormone replacement therapy (HOURST) for a period of at least 2 months will not be excluded from the study, provided the HOURST regimen remains unchanged during the conduct of the study.
13. Any concomitant medications that prolong QT/QTc interval.
14. Dosed with an investigational drug within 30 days or 5 elimination half-lives (whichever is longer) prior to study drug administration.
15. Received any systemic steroid within 1 month or systemic immunosuppressant agent within 6 months prior to study drug administration.
16. Received any antibody therapy or biologic products within 6 months prior to study drug administration.
17. Significant loss of blood including blood donation over 500 mL or transfusion of any blood product within 3 months before the Screening Visit.
18. Unwilling to refrain alcohol use 48 hours prior to your admission into the clinical research unit.
19. Known hypersensitivity, allergy or intolerance to the study drug or any of the excipient contained in the intervention formulation.
20. Immunisation with any vaccine within 6 weeks prior to study drug administration.
21. For participants enrolled in cohorts in which KLH will be administered: known administration of KLH within 6 months prior to study drug administration; known seafood or shellfish allergy, or known hypersensitivity or allergy to KLH Laboratory Exclusions
22. Any clinically significant (at the discretion of the Investigator) abnormalities in laboratory test results, including complete blood count, chemistry panels and urinalysis. If out of range at the Screening Visit and/or admission to the CRU and deemed clinically significant by investigator, the tests may be repeated once on a separate day.
23. Estimated creatinine CL < 90 mL/minute at the Screening Visit
24. Positive test at the Screening Visit and/or at baseline for drugs of abuse (e.g., phencyclidine, opiates, benzodiazepines, barbiturates, amphetamines, methamphetamines, cocaine and THC). The repeat test is permitted once for a suspected false positive test.
25. Positive alcohol breath test at the Screening Visit and/or at baseline.
26. Positive result on tests for HIV-1 and/or HIV-2 antibody, anti-hepatitis B virus antibodies (core antibody [HBcAb], surface antigen [HBsAg]) or anti-hepatitis C virus antibody.
27. Positive serum pregnancy test at the Screening Visit or admission to the CRU. Infection-related Exclusions.
28. Acute infection including viral infections in the preceding 6 weeks

29. History or presence of any chronic infectious condition, including but not limited to tuberculosis or parasitic infections. Evidence of tuberculosis may include either a positive tuberculosis blood test (by a positive QuantiFERON® TB-Gold test or a positive tuberculin skin test) or chest X-ray radiographic findings consistent with active or latent tuberculosis.

    Cardiovascular Exclusions

30. Supine sustained (i.e. 3 independent measurements within 30 min) systolic blood pressure greater than 140 or less than 90 mmHg.
31. Supine sustained (i.e. 3 independent measurements within 30 min) diastolic blood pressure greater than 90 or less than 40 mmHg.
32. Sustained (i.e. 3 independent measurements within 30 min) heart rate (pulse) greater than 100 or less than 40 beats per minute (bpm).
33. QTcF < 300 msec or ≥ 450 msec.
34. Personal and/or family history of congenital long QT syndrome or sudden cardiac death

Contacts and Locations

Locations

Australia, Victoria

Nucleus Network- Centre for Clinical Studies

Melbourne, Victoria, Australia, 3004

Sponsors and Collaborators

Alpine Immune Sciences, Inc.

Clinical Network Services (CNS) Pty Ltd

More Information

• Responsible Party: Alpine Immune Sciences, Inc.
• ClinicalTrials.gov Identifier: NCT03748836
• Other Study ID Numbers: AIS-A01
• First Posted: November 21, 2018
• Last Update Posted: December 5, 2019
• Last Verified: October 2019

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by Alpine Immune Sciences, Inc.:

Healthy Volunteers